Breaking News

Otsuka Acquires Rights to Eisai’s Dacogen

Gains development and commercialization rights in the U.S., Canada and Japan

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eisai, Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., has sold the rights to DACOGEN (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd. DACOGEN is approved for treatment of patients with myelodysplastic syndromes   Through an exclusive worldwide license, Otsuka gains full development and commercialization rights for the product in the former Eisai territories of the U.S., Canada and Japan. Eisai will retain its rights for DACOGEN in Mexico. Otsuka will also gain the patent for Eis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters